Clinical Trial Update: A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

View source ↗

Summary

The CONKO-003 Phase III trial in second-line therapy for advanced pancreatic cancer has resulted in regulatory approval for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: CONKO-Studiengruppe | Conditions: Pancreatic Cancer | Status: APPROVED_FOR_MARKETING